Use of Intravenous Immunoglobulins for Prophylaxis or Treatment of Infectious Diseases

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Clinical Diagnostic Laboratory Immunology

• Publication date

  2001-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1128/CDLI.8.5.859-863.2001PMID 11527792PMCID PMC96160
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An Introduction to the Study of Infection and Immunity, Including Chapters on Serum Therapy, Vaccine Therapy, Chemotherapy and Serum Diagnosis for Students and Practitioners

  2010cited by this paper
• Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection

  2000cited by this paper
• Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants.

  2000cited by this paper
• Prevention of infection in multiple trauma patients by high‐dose intravenous immunoglobulins

  2000cited by this paper
• Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

  2000cited by this paper
• Additional confirmation of the lack of effect of intravenous immunoglobulin in the prevention of neonatal infection.

  2000cited by this paper
• Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group.

  2000cited by this paper
• Preterm infants with low immunoglobulin G levels have increased risk of neonatal sepsis but do not benefit from prophylactic immunoglobulin G.

  2000cited by this paper
• Antibodies and resistance to natural HIV infection.

  2000influential reference
• Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185.

  1999cited by this paper
• Supplemental Immune Globulins in Sepsis

  1999cited by this paper
• Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants.

  1998cited by this paper
• Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.

  1998cited by this paper
• Reduction of Respiratory Syncytial Virus Hospitalization Among Premature Infants and Infants with Bronchopulmonary Dysplasia Using Respiratory Syncytial Virus Immune Globulin Prophylaxis

  1997cited by this paper
• Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation

  1997cited by this paper
• Human intravenous immunoglobulin in primary and secondary antibody deficiencies.

  1997cited by this paper
• Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group.

  1997cited by this paper
• Human intravenous immunoglobulin in primary and secondary antibody deficiencies.

  1997cited by this paper
• Respiratory Syncytial Virus (RSV) Immune Globulin Intravenous Therapy for RSV Lower Respiratory Tract Infection in Infants and Young Children at High Risk for Severe RSV Infections

  1997cited by this paper
• Safety and Pharmacokinetics of Hyperimmune Anti-Human Immunodeficiency Virus (HIV) Immunoglobulin Administered to HIV-Infected Pregnant Women and Their Newborns

  1997cited by this paper
• Randomized comparison of ganciclovir plus intravenous immune globulin (IVIG) with IVIG alone for prevention of primary cytomegalovirus disease in children receiving liver transplants.

  1997cited by this paper
• Prevention and treatment recommendations for respiratory syncytial virus infection. Background and clinical experience 40 years after discovery.

  1997cited by this paper
• Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group.

  1997cited by this paper
• Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children.

  1997cited by this paper
• Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections

  1995cited by this paper
• A CONTROLLED TRIAL OF INTRAVENOUS IMMUNE GLOBULIN FOR THE PREVENTION OF SERIOUS BACTERIAL INFECTIONS IN CHILDREN RECEIVING ZIDOVUDINE FOR ADVANCED HUMAN IMMUNODEFICIENCY VIRUS INFECTION

  1995cited by this paper
• Intravenous immunoglobins (IVIGs) to prevent and treat infectious diseases.

  1995cited by this paper
• Crossover of placebo patients to intravenous immunoglobulin confirms efficacy for prophylaxis of bacterial infections and reduction of hospitalizations in human immunodeficiency virus‐infected children

  1994cited by this paper
• A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network.

  1994cited by this paper
• A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group.

  1994cited by this paper
• Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children

  1994cited by this paper
• Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.

  1993cited by this paper
• Comparison of group B streptococcal hyperimmune globulin and standard intravenously administered immune globulin in neonates.

  1993cited by this paper
• INTRAVENOUS IMMUNE GLOBULIN FOR THE PREVENTION OF NOSOCOMIAL INFECTION IN LOW BIRTHWEIGHT NEONATES

  1993cited by this paper
• Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-Risk Infants and Young Children

  1993cited by this paper
• Intravenous immune globulin for the prevention of nosocomial infection in low-birth-weight neonates. The Multicenter Group for the Study of Immune Globulin in Neonates.

  1992cited by this paper
• Intravenous immune globulin therapy for early-onset sepsis in premature neonates.

  1992cited by this paper
• Final analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus-immune globulin: comparison of the randomized and open-label trials.

  1991cited by this paper
• Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus-seropositive donors.

  1991cited by this paper
• Report of the Committee on Infectious Diseases

  1989cited by this paper
• Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients.

  1987cited by this paper
• Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children

  1987cited by this paper
• Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat.

  1985cited by this paper
• Studies of passive immunotherapy for infections of respiratory syncytial virus in the respiratory tract of a primate model.

  1985cited by this paper
• Giant cell pneumonia due to respiratory syncytial virus.

  1985cited by this paper
• A pilot trial of a novel cytomegalovirus immune globulin in renal transplant recipients.

  1984cited by this paper
• Prevention of cytomegalovirus infection in bone marrow transplant recipients by prophylaxis with an intravenous, hyperimmune cytomegalovirus globulin.

  1984cited by this paper
• Functional Antibacterial Activity of a Human Intravenous Immunoglobulin Preparation: in vitro and in vivo Studies

  1983cited by this paper
• USE OF NORMAL IMUNOGLOBULIN IN AN ECHOVIRUS 11 OUTBREAK IN A SPECIAL-CARE BABY UNIT

  1983cited by this paper
• Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation.

  1983cited by this paper
• Successful treatment of echovirus meningoencephalitis and myositis-fasciitis with intravenous immune globulin therapy in a patient with X-linked agammaglobulinemia.

  1981cited by this paper
• Standard and special human immune serum globulins as therapeutic agents.

  1979cited by this paper
• Assessment of group B streptococcal opsonins in human and rabbit serum by neutrophil chemiluminescence.

  1976cited by this paper
• The effect of monthly gamma-globulin administration on morbidity and mortality from infection in premature infants during the first year of life.

  1963cited by this paper
• Serum gamma globulin levels in normal infants.

  1955cited by this paper
• Agammaglobulinemia.

  1952cited by this paper
• The Acute Bacterial Diseases: Their Diagnosis and Treatment

  1949cited by this paper
• The pneumonias.

  1946cited by this paper
• CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. XI. THE USE OF CONCENTRATED NORMAL HUMAN SERUM GAMMA GLOBULIN (HUMAN IMMUNE SERUM GLOBULIN) IN THE PROPHYLAXIS AND TREATMENT OF MEASLES.

  1944cited by this paper
• CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. I. THE CHARACTERIZATION OF THE PROTEIN FRACTIONS OF HUMAN PLASMA.

  1944cited by this paper
• CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. XII. THE USE OF CONCENTRATED NORMAL HUMAN SERUM GAMMA GLOBULIN (HUMAN IMMUNE SERUM GLOBULIN) IN THE PREVENTION AND ATTENUATION OF MEASLES.

  1944cited by this paper
• The Prevention and Attenuation of Measles

  1933cited by this paper

• Intravenous immunoglobulin in severe Crimean-Congo hemorrhagic fever: A retrospective study

  2026cites this paper
• Rituximab combined with intravenous immunoglobulin in autoimmune diseases: a systematic review

  2025cites this paper
• Simultaneous Isolation and Purification of Transferrin and Immunoglobulin G from Human Serum—A New Biotech Solution

  2025cites this paper
• Novel Intravenous Immunoglobulin Therapy for the Prevention and Treatment of Candida auris and Candida albicans Disseminated Candidiasis

  2023cites this paper
• Adjuvant intravenous immunoglobulin administration on postoperative critically ill patients with secondary peritonitis: a retrospective study

  2023cites this paper
• Treatment of Recurrent VZV Myelitis with Intravenous Immunoglobulin

  2023cites this paper
• Bovine-derived antibodies and camelid-derived nanobodies as biotherapeutic weapons against SARS-CoV-2 and its variants: A

  2022cites this paper
• Impact of Convalescent Plasma Therapy in Hospitalized Patients With Severe COVID-19

  2022cites this paper
• Transchromosomic bovines‐derived broadly neutralizing antibodies as potent biotherapeutics to counter important emerging viral pathogens with a special focus on SARS‐CoV‐2, MERS‐CoV, Ebola, Zika, HIV‐1, and influenza A virus

  2022cites this paper
• Transfusing convalescent plasma as post-exposure prophylaxis against SARS-CoV-2 infection: a double-blinded, phase 2 randomized, controlled trial

  2022cites this paper
• In vitro and in vivo methods to study bacterial colonization of hydrogel dermal fillers.

  2022cites this paper
• Bovine-derived antibodies and camelid-derived nanobodies as biotherapeutic weapons against SARS-CoV-2 and its variants: A review article

  2022cites this paper
• Randomized controlled trial transfusing convalescent plasma as post-exposure prophylaxis against SARS-CoV-2 infection

  2021cites this paper
• Efficacy of intravenous immunoglobulins in the prophylaxis of neonatal sepsis

  2021cites this paper
• Promiscuous Biological Features of Newly Emerged SARS-CoV-2 Facilitate its Unrestrained Outbreak: An Update

  2021cites this paper
• SARS-CoV (COVID-19) Pandemic—Detailed Insights into Diagnosis, Management, and Role of Indian Herbal Drugs

  2021cites this paper
• Application of intravenous immunoglobulin (IVIG) to modulate inflammation in critical COVID-19 – A theoretical perspective

  2021cites this paper
• Don't Be a Stiff

  2021cites this paper
• The Ability of Zika virus Intravenous Immunoglobulin to Protect From or Enhance Zika Virus Disease

  2021cites this paper
• The Effect of Container Surface Passivation on Aggregation of Intravenous Immunoglobulin Induced by Mechanical Shock

  2020cites this paper
• Diagnosis and clinical management of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection: an operational recommendation of Peking Union Medical College Hospital (V2.0)

  2020influential citation
• Emerging small and large molecule therapeutics for respiratory syncytial virus

  2020cites this paper
• Convalescent Plasma Therapy and its Century-Old Untapped Potential for COVID-19

  2020cites this paper
• Convalescent Plasma Therapy for Pandemics, COVID-19 as example: A Mini Review

  2020cites this paper
• Immunogenic properties of immunoglobulin superfamily members within complex biological networks

  2020cites this paper
• Convalescent Blood Products in COVID-19: A Narrative Review

  2020cites this paper
• Plasma-derived therapy: can the survivors of COVID-19 help the defenseless?

  2020cites this paper
• Plasma Donors in the Southwestern United States Positively Contribute to the Diverse Therapeutic Antibody Profile of Immune Globulin Products

  2020cites this paper
• Silica resins and peptide ligands to develop disposable affinity adsorbents for antibody purification

  2019cites this paper
• The Effectiveness of Different Doses of Intravenous Immunoglobulin on Severe Hand, Foot and Mouth Disease: A Meta-Analysis

  2019cites this paper
• The risk of hospitalization for respiratory tract infection (RTI) in children who are treated with high-dose IVIG in Kawasaki Disease: a nationwide population-based matched cohort study

  2018cites this paper
• Reversing Autoimmunity Combination of Rituximab and Intravenous Immunoglobulin

  2018cites this paper
• Intravenous Immunoglobulin Protects Against Severe Pandemic Influenza Infection

  2017cites this paper
• Current and future treatment options for pemphigus: Is it time to move towards more effective treatments?

  2017cites this paper
• Detailed Protocols for the Selection of Antiviral Human Antibodies from Combinatorial Immune Phage Display Libraries

  2017cites this paper
• Convalescent plasma: new evidence for an old therapeutic tool?

  2016cites this paper
• Natural and artificial hyperimmune solutions: Impact on health in puppies

  2016cites this paper
• Managing patients with side effects and adverse events to immunoglobulin therapy

  2016cites this paper
• Production of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal Cattle

  2016cites this paper
• The use of Immunoglobulin Therapy in Primary Immunodeficiency Diseases.

  2016cites this paper
• Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases.

  2015cites this paper
• Immunotherapy for Infectious Diseases: Past, Present, and Future

  2015cites this paper
• Production of potent fully human polyclonal antibodies against Zaire Ebola virus in transchromosomal cattle

  2015cites this paper
• Immunization Practice in Pediatric Oncology

  2015cites this paper
• eview olecular properties of human IgG subclasses and their implications or designing therapeutic monoclonal antibodies against infectious iseases

  2015cites this paper
• Intravenous Administration of Chicken Immunoglobulin Has a Curative Effect in Experimental Infection of Canine Parvovirus

  2014cites this paper
• De la sueroterapia a los anticuerpos monoclonales: nuevas perspectivas en el tratamiento de las enfermedades infecciosas del niño

  2014cites this paper
• Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity in intravenous immunoglobulin as a potential therapeutic against emerging influenza viruses.

  2014cites this paper
• Generation of "LYmph Node Derived Antibody Libraries" (LYNDAL) : a concept for recovering human monoclonal antibodies with therapeutic potential

  2014cites this paper
• Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases

  2013cites this paper
• The anti-inflammatory properties of intravenous immunoglobulin in a murine model of allergic airway disease ; effects on the development of regulatory T-cells

  2013cites this paper
• An augmented passive immunotherapy to treat pneumococcal diseases

  2012cites this paper
• Role of passive immunotherapies in managing infectious outbreaks.

  2012cites this paper
• P4-mediated antibody therapy in an acute model of invasive pneumococcal disease.

  2012cites this paper
• [Mechanism of intravenous immunoglobulin therapy for severe hand-foot-mouth disease: a review].

  2011cites this paper
• Human Monoclonal Antibodies for Prophylaxis and Treatment of Influenza

  2011cites this paper
• Efficacy of Hyperimmunized Plasma in the Treatment of Horses with Acute Colitis

  2011cites this paper
• Monomeric and Dimeric IgG Fractions Show Differential Reactivity Against Pathogen‐Derived Antigens

  2011cites this paper
• Convalescent transfusion for pandemic influenza: preparing blood banks for a new plasma product?

  2010cites this paper
• Ensaio imunoenzimático para o diagnóstico da hepatite A utilizando IgY anti-HAV

  2010cites this paper
• Novel strategies for controlling Streptococcus pyogenes infection and associated diseases: from potential peptide vaccines to antibody immunotherapy

  2009cites this paper
• Intravenous immunoglobulin-based immunotherapy: an arsenal of possibilities for patients and science.

  2009cites this paper
• Intravenous IgG: biological modulating molecules.

  2009cites this paper
• Neutralizing Anti-Influenza Virus Monoclonal Antibodies: Therapeutics and Tools for Discovery

  2009cites this paper
• Monomerization of dimeric IgG of intravenous immunoglobulin (IVIg) increases the antibody reactivity against intracellular antigens.

  2008cites this paper
• The growth and potential of human antiviral monoclonal antibody therapeutics

  2007cites this paper
• Immune reconstitution after autologous hematopoietic stem cell transplantation

  2007cites this paper
• Efficacy of hyperimmunized plasma in the treatment of horses with acute diarrhea

  2007cites this paper
• The Role of Prolactin in CCL28 Regulation

  2007cites this paper
• Immunoglobulin is a highly diverse self-molecule that improves cellular diversity and function during immune reconstitution.

  2007cites this paper
• Combinatorial Phage Antibody Libraries

  2006cites this paper
• Immuno-modulation in neonatal sepsis : intravenous immunoglobulin therapy in the prevention and treatment of neonatal sepsis : Is the answer , ‘ Yes ’ , ‘ No ’ , or ‘ Don ’ t know ’ ?

  2006cites this paper
• Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment?

  2006cites this paper
• Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era?

  2004cites this paper
• Passive immunization for immunocontraception: lessons learned from infectious diseases.

  2004cites this paper
• Microarray profiling of antiviral antibodies for the development of diagnostics, vaccines, and therapeutics.

  2004cites this paper
• Intravenous immunoglobulin for infectious diseases: tailor-made or universal?

  2003cites this paper
• Research Article Design and evaluation of a diabody to improve protection against a potent scorpion neurotoxin

  2003cites this paper
• Simultaneous isolation and purification of transferrin and immunoglobulin G from human serum – a new biotech method

  year unknowncites this paper